Glioblastoma Awareness Day

Today is Glioblastoma Awareness Day, highlighting the need for improved treatment options for this aggressive type of brain cancer.

At MRC Holland, we are humbled to make a small contribution to the understanding of glioblastoma, by developing products that allow researchers and clinicians to study the role of gene copy number and methylation changes in this devastating disorder:

• SALSA^® MLPA^® Probemix P088 Oligodendroglioma 1p-19q allows the detection of co-deletion of chromosome arms 1p and 19q, deletions of the CDKN2A and CDKN2B genes and the most common somatic point mutations in IDH1 (p.R132H and p.R132C) and IDH2 (p.R172K and p.R172M).

• SALSA^® MLPA^® Probemix P105 Glioma-2 allows the detection of deletions or duplications in the following genes PDGFRA (4q12), EGFR (7p11.2), CDKN2A (9p21.3), PTEN (10q23.31), CDK4, MIR26A2, MDM2 (12q14-q15), NFKBIA (14q13.2) and TP53 (17p13.1).

• SALSA^® MLPA^® Probemix P370 BRAF-IDH1-IDH2 allows the detection of the BRAF p.V600E and four predominant IDH1 (p.R132H and p.R132C) and IDH2 (p.R172M and p.R172K) point mutations, duplications leading to the SRGAP3-RAF1, KIAA1549-BRAF and FGFR1-TACC1 fusion genes and copy number aberrations in the BRAF, CDKN2A/2B, FGFR1, MYB and MYBL1 genes.

• SALSA^® MLPA^® Probemix ME012 MGMT-IDH-TERT allows the detection of aberrant methylation of the MGMT gene and IDH1 (p.R132H=c.395G>A and p.R132C=c.394C>T), IDH2 (p.R172K=c.515G>A and p.R172M=c.515G>T), TERT promoter (C228T and C250T) point mutations.